Shares of ProAssurance (PRA) have gained 10.1% over the past four weeks to close the last trading session at $13.40, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $16.75 indicates a potential upside of 25%. The mean estimate comprises four short-term price targets with a standard deviation of $2.75. While the lowest estimate of $14 indicates a 4.5% increase from the current pr ...

ProAssurance (PRA) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this medical professional liability insurer, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends i ...

Shares of ProAssurance (PRA) have gained 10.6% over the past four weeks to close the last trading session at $13.12, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $16.75 indicates a potential upside of 27.7%. The average comprises four short-term price targets ranging from a low of $14 to a high of $20, with a standard deviation of $2.75. While the lowest estimate indicates an ...

ProAssurance Corporation (PRA) reported second-quarter 2024 adjusted operating income of 23 cents per share, which surpassed the Zacks Consensus Estimate of 8 cents. The bottom line soared 64.3% year over year. Operating revenues dipped 1.1% year over year to $279 million. The top line beat the consensus mark by 1.8%. ProAssurance's quarterly performance was bolstered by strong underwriting results in the Specialty P&C segment, significant growth in investment income driven by a higher interest rate environ ...

Core Insights - ProAssurance reported revenue of $278.54 million for Q2 2024, a year-over-year decline of 1.3%, with an EPS of $0.23 compared to $0.16 a year ago, indicating a significant EPS surprise of +187.50% against the consensus estimate of $0.08 [1] Financial Performance Metrics - Combined Ratio was reported at 110.9%, better than the average estimate of 112.4% from five analysts [3] - Underwriting Expense Ratio stood at 33.4%, higher than the average estimate of 31.6% from five analysts [4] - Net Loss Ratio was 77.5%, outperforming the average estimate of 80.7% from five analysts [5] - Underwriting Expense Ratio for Workers Compensation was 36.2%, above the average estimate of 34.4% from three analysts [6] - Net Premiums Earned totaled $239.87 million, slightly above the average estimate of $235.03 million from five analysts, reflecting a year-over-year decline of 3.2% [7] - Net Investment Income was reported at $36.56 million, exceeding the average estimate of $34.47 million from five analysts, marking a year-over-year increase of 15.5% [8] - Equity in earnings of unconsolidated subsidiaries was $8.65 million, significantly higher than the average estimate of $2.58 million from five analysts [9] - Other income was reported at $2.12 million, below the average estimate of $3.44 million from five analysts, representing a year-over-year decline of 22.8% [10] - Net Premiums Earned in Specialty Property & Casualty was $184.55 million, slightly above the average estimate of $184.45 million from three analysts, showing a year-over-year increase of 3.2% [10] - Net Premiums Earned in Segregated Portfolio Cell Reinsurance was $13.55 million, below the average estimate of $14.56 million from three analysts, reflecting a significant year-over-year decline of 43.8% [11] - Net Premiums Earned in Workers Compensation was $41.77 million, exceeding the average estimate of $41.04 million from three analysts, with a year-over-year increase of 1.8% [12] - Net Investment Income in Segregated Portfolio Cell Reinsurance was $0.99 million, surpassing the average estimate of $0.71 million from two analysts, indicating a year-over-year increase of 63.4% [13] Stock Performance - ProAssurance shares have returned +2.3% over the past month, contrasting with the Zacks S&P 500 composite's decline of -6.5%, and the stock currently holds a Zacks Rank 3 (Hold) [13]

ProAssurance (PRA) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 187.50%. A quarter ago, it was expected that this medical professional liability insurer would post earnings of $0.04 per share when it actually produced earnings of $0.08, delivering a surprise of 100%. Over the last ...

ProAssurance Corporation (PRA) is set to report its second-quarter 2024 results on Aug 8, after the closing bell. The Zacks Consensus Estimate for second-quarter earnings is currently pegged at 8 cents per share, implying a decline of 50% from the year-ago reported number. The estimate remained stable over the past month. The Zacks Consensus Estimate for second-quarter revenues is currently pegged at almost $273.7 million, suggesting a 3.1% fall from the year-ago actuals. Image Source: Zacks Investment Rese ...

In its upcoming report, ProAssurance (PRA) is predicted by Wall Street analysts to post quarterly earnings of $0.08 per share, reflecting a decline of 50% compared to the same period last year. Revenues are forecasted to be $273.65 million, representing a year-over-year decrease of 3.1%. Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. ...

The price trend for ProAssurance (PRA) has been bearish lately and the stock has lost 8.4% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support. While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts ...

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30. Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and e ...